Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Envafolimab in PD-1–resistant NSCLC
CTR20212194Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, envafolimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Sep 2021; status: completed.
02
Drugs
tucidinostatenvafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212194.